Journal of Immunology Research / 2018 / Article / Tab 2 / Review Article
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials Table 2 Patients’ baseline characteristics and disease-related demographics of included studies.
Study CASTOR POLLUX ELOQUENT-2 NCT01478048 PANORAMA1 VANTAGE088 E C E C E C E C E C E C Number of patients 251 247 286 283 321 325 77 75 387 381 317 320 Median age (year) 64 64 65 65 67 66 65 65 63 63 61 63 ECOG performance status 0 NA NA 139 (48.6) 150 (53.0) NA NA 38 (49.4) 46 (61.3) 175 (45.2) 162 (42.5) 126 (39.7) 119 (37.2) 1 NA NA 1 o r2: 1 or 2: NA NA 35 (45.5) 23 (30.7) 191 (49.4) 186 (48.8) 164 (51.7) 167 (52.2) 2 NA NA NA NA 2 (0.03) 6 (8.0) 19 (4.9) 29 (7.6) 24 (7.6) 34 (10.6) ISS disease staging I 98 (39.0) 96 (38.9) 137 (47.9) 140 (49.5) 141 (43.9) 138 (42.5) 26 (33.8) 19 (25.3) 156 (40.3) 152 (39.9) 95 (30.0) 80 (25.0) II 94 (37.5) 100 (40.5) 93 (32.5) 86 (30.4) 102 (31.8) 105 (32.3) 23 (29.9) 20 (26.7) 104 (26.9) 92 (24.1) 98 (30.9) 99 (30.9) III 59 (23.5) 51 (20.6) 56 (19.6) 57 (20.1) 66 (20.6) 68 (20.9) 11 (14.3) 16 (21.3) 77 (19.9) 86 (22.6) 87 (27.4) 82 (25.6) Not assessed 12 (0.04) 14 (0.04) 17 (22.1) 20 (26.7) 50 (12.9) 51 (13.4) 37 (11.7) 59 (18.4) Previous lines of therapy 1 122 (48.6) 113 (45.7) 149 (52.1) 146 (51.6) 151 (47.0) 159 (48.9) 50 (64.9) 51 (68.0) 197 (50.9) 198 (52.0) 143 (45.1) 127 (39.7) 2 70 (27.9) 74 (30.0) 85 (29.7) 80 (28.3) 118 (36.8) 114 (35.1) 2 or more: 27 2 or more: 24 124 (32.0) 108 (28.3) 105 (33.1) 134 (41.9) 3 or more 59 (23.5) 60 (24.3) 52 (18.2) 57 (20.1) 52 (16.2) 52 (16.0) 64 (16.5) 75 (19.7) 69 (21.8) 59 (18.4) Previous stem-cell transplantation Yes 156 (62.2) 149 (60.3) 180 (62.9) 180 (63.6) 167 (52.0) 185 (56.9) 39 (50.6) 41 (54.7) 215 (55.6) 224 (58.8) 113 (35.6) 115 (35.9) No 95 (37.8) 98 (39.7) 106 (37.1) 103 (36.4) 154 (48.0) 140 (43.1) 38 (49.4) 34 (45.3) 172 (44.4) 157 (41.2) 204 (64.4) 205 (64.1) Drugs used in previous treatment Proteasome inhibitors 179 (71.3) 198 (80.2) 245 (85.7) 242 (85.5) 219 (68.2) 231 (71.1) 39 (50.6) 40 (53.3) 169 (43.7) 161 (42.3) 79 (24.9) 73 (22.8) Immunomodulatory drugs 169 (67.3) 172 (69.6) 158 (55.2) 156 (55.1) 169 (52.6) 178 (54.8) 55 (71.4) 58 (77.3) 277 (71.6) 273 (71.7) 192 (60.6) 208 (65.0) Alkylating agents 240 (95.6) 224 (90.7) 268 (93.7) 270 (95.4) 220 (68.5) 197 (60.6) NA NA 300 (77.5) 268 (70.3) NA NA
NA: not available; E: experimental group; C: control group.
